Bionomics Limited to Participate in Upcoming November Investor Conferences
02 nov. 2022 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
27 oct. 2022 17h10 HE
|
Vyant Bio, Inc.
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vyant...
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
27 oct. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Quarterly Activities Report for September 2022
25 oct. 2022 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
24 oct. 2022 16h15 HE
|
Vyant Bio, Inc.
-To Discuss its Novel Drug Discovery Platform that is Accelerating the Process of Finding Cures for Neurogenerative Diseases CHERRY HILL, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc....
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
21 oct. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, November 7, 2022 at 8:00 AM Eastern Time NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
20 oct. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week1-4 ...
Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting
11 oct. 2022 11h15 HE
|
Ambit Inc.
CINCINNATI, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambit®, a data and technology-enabled biopharma services company, today announced that leadership will debut Ambit's data-driven methodology for...
Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference
04 oct. 2022 06h00 HE
|
Bionomics Ltd
ADELAIDE, Australia, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
29 sept. 2022 07h28 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...